Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TVTX | US
-0.05
-0.63%
Healthcare
Biotechnology
31/03/2024
05/07/2024
7.89
7.88
7.96
7.72
Travere Therapeutics Inc. a biopharmaceutical company focuses on the identification development commercialization and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058 a novel investigational human enzyme replacement candidate which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations CDG Care and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin Inc. and changed its name to Travere Therapeutics Inc. in November 2020. Travere Therapeutics Inc. was incorporated in 2008 and is headquartered in San Diego California.
View LessLow Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Price Below SMA10D
Smallcap (300M - 2B USD)
High Short percentage (> 15%)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
47.6%1 month
51.5%3 months
57.9%6 months
64.9%-
-
2.41
5.45
0.61
-0.99
2.22
-
-376.56M
600.66M
600.66M
-
-335.91
-
33.90
-315.89
13.87
19.83
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.40
Range1M
1.59
Range3M
3.27
Rel. volume
0.36
Price X volume
3.32M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
UroGen Pharma Ltd | URGN | Biotechnology | 15.88 | 653.15M | 5.80% | n/a | -246.69% |
Sage Therapeutics Inc | SAGE | Biotechnology | 10.78 | 648.76M | 1.51% | n/a | 0.47% |
Pliant Therapeutics Inc. | PLRX | Biotechnology | 10.52 | 634.63M | -0.57% | n/a | 12.50% |
Humacyte Inc | HUMA | Biotechnology | 5.27 | 627.57M | -7.05% | n/a | 71.00% |
Scholar Rock Holding Corporation | SRRK | Biotechnology | 7.74 | 617.30M | -0.39% | n/a | 32.90% |
Savara Inc | SVRA | Biotechnology | 4.43 | 612.18M | 2.31% | n/a | 21.80% |
GH Research PLC Ordinary Shares | GHRS | Biotechnology | 11.75 | 611.33M | -2.49% | n/a | 0.43% |
Lexicon Pharmaceuticals Inc | LXRX | Biotechnology | 1.67 | 603.69M | 0.60% | n/a | 36.78% |
PHATHOM PHARMACEUTICALS INC. | PHAT | Biotechnology | 10.3 | 602.91M | 0.49% | n/a | -315.85% |
Mineralys Therapeutics Inc. | MLYS | Biotechnology | 12.43 | 597.61M | 2.30% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Ennis Inc | EBF | Building Products & Equipment | 21.25 | 552.16M | -0.75% | 13.68 | 1.15% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 4.48 | 428.47M | -2.40% | n/a | 138.85% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 25.77 | 412.92M | -1.68% | n/a | 322.60% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.74 | 369.15M | -2.49% | 14.12 | 86.68% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.36 | 324.63M | -2.40% | 10.10 | 0.00% |
Latham Group Inc. | SWIM | Building Products & Equipment | 2.74 | 316.67M | -3.52% | 75.75 | 80.81% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.55 | 298.02M | -0.34% | 8.24 | 25.57% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 26.52 | 294.97M | -4.29% | 17.47 | -562.47% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 12.93 | 209.56M | -2.78% | 8.94 | 15.44% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 44.59 | 128.20M | -4.23% | 7.40 | 89.91% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.99 | -2.43 | Expensive |
Ent. to Revenue | 2.22 | 4,101.76 | Cheaper |
PE Ratio | - | 41.26 | - |
Price to Book | 2.41 | 22.34 | Cheaper |
Dividend Yield | - | 2.39 | - |
Std. Deviation (3M) | 57.87 | 76.52 | Lower Risk |
Debt to Equity | 5.45 | 0.51 | Expensive |
Debt to Assets | 0.61 | 0.24 | Expensive |
Market Cap | 600.66M | 3.77B | Emerging |